Halozyme gives preliminary 2025 revenue of $1,385–$1,400M
Halozyme Therapeutics provides preliminary, unaudited estimates for its 2025 results, including total revenue between $1,385 million and $1,400 million.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Halozyme Therapeutics provides preliminary, unaudited estimates for its 2025 results, including total revenue between $1,385 million and $1,400 million. The company estimates 2025 royalties of $865 million to $870 million, product sales of $372 million to $377 million, and collaboration revenue of $148 million to $153 million. These figures were shared in connection with 2026 financial guidance and remain subject to completion of year-end financial closing procedures.
Insights
Halozyme shares sizable 2025 revenue mix, but numbers are preliminary.
Halozyme outlines estimated 2025 revenue of $1,385 million to $1,400 million, broken into royalties, product sales, and collaboration revenue. The largest component is royalties, estimated at $865 million to $870 million, highlighting continued reliance on partnered products.
Because these figures are unaudited preliminary estimates, they may change as year-end close is completed. The company also referenced updated 2026 guidance and a business update, so subsequent filings and the Form 10-K for the year ended December 31, 2025 will give the finalized financial picture.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What 2025 revenue is Halozyme Therapeutics (HALO) estimating in its latest 8-K?
Halozyme is estimating 2025 total revenue between $1,385 million and $1,400 million. This preliminary, unaudited range was provided alongside 2026 financial guidance and is subject to adjustment when final year-end closing and the 2025 Form 10-K are completed.
How much 2025 royalty revenue does Halozyme Therapeutics (HALO) preliminarily expect?
Halozyme preliminarily expects 2025 royalty revenue between $865 million and $870 million. These unaudited estimates are based on information available as of the investor conference call date and may change once full financial and accounting close procedures for 2025 are finalized.
What are Halozyme Therapeutics’ (HALO) estimated 2025 product sales and collaboration revenue?
For 2025, Halozyme estimates product sales of $372 million to $377 million and collaboration revenue of $148 million to $153 million. These figures are preliminary, unaudited, and intended as guidance ahead of final results in the company’s 2025 Form 10-K filing.
Are Halozyme Therapeutics’ (HALO) 2025 financial estimates in the 8-K final numbers?
No, the 2025 figures are preliminary, unaudited estimates. They were shared with investors to frame expectations but remain subject to completion of financial close processes, meaning the final numbers in the 2025 Form 10-K could differ, potentially materially.
What else did Halozyme Therapeutics (HALO) discuss with investors alongside the 2025 estimates?
Alongside the preliminary 2025 estimates, Halozyme issued a press release and held a conference call to provide updated 2026 financial guidance and a business update. Slide materials and the press release were used to communicate the estimates and broader outlook to investors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | ||||||||
(Exact name of registrant as specified in its charter)
________________________
Commission File Number 001-32335
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | |||||||
| (Zip Code) | ||||||||
| (Address of principal executive offices) | ||||||||
(858 ) 794-8889
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 28, 2026, Halozyme Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release containing information related to the Company’s 2026 financial guidance (the “Press Release”). The Press Release included certain preliminary, unaudited estimates regarding the Company’s financial results for the year ended December 31, 2025 (together with the preliminary estimates set forth below, the “Preliminary 2025 Estimates”). A copy of the Press Release is attached as Exhibit 99.1.
On January 28, 2026, the Company hosted an investor conference call (the “Conference Call”) to provide updated 2026 guidance and a business update. The slides used by the Company during the Conference Call presentation included certain preliminary, unaudited estimates regarding the Company’s financial results for the year ended December 31, 2025, which are also set forth below.
The financial results presented below are preliminary, estimated, and unaudited. They are subject to the completion and finalization of the Company’s financial and accounting close procedures. They reflect management’s estimates based solely upon information available to management as of the date of the Conference Call presentation. Further information learned during the completion and finalization of these procedures may alter the final results. These preliminary estimates should not be considered a substitute for the financial information to be filed with the Securities and Exchange Commission on the Company’s Form 10-K for the year ended December 31, 2025 once it becomes available. There is a possibility that the Company’s financial results for the twelve months ended December 31, 2025 could vary materially from these preliminary estimates. Accordingly, you should not place undue reliance upon this preliminary information.
Unaudited Preliminary Estimates of Results for the Twelve Months Ended December 31, 2025
The Company estimates 2025 Revenue will be in the range of $1,385 million to $1,400 million.
The Company estimates 2025 Royalties will be in the range of $865 million to $870 million.
The Company estimates 2025 Product Sales will be in the range of $372 million to $377 million.
The Company estimates 2025 Collaboration Revenue will be in the range of $148 million to $153 million.
The Press Release and Preliminary 2025 Estimates are furnished under Item 2.02 of this report and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
| Exhibit No. | Description | |||||||
99.1 | Press release dated January 28, 2026 | |||||||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Halozyme Therapeutics, Inc. (Registrant) | |||||||||||||||||
Dated: | January 28, 2026 | By: | /s/ Nicole LaBrosse | ||||||||||||||
| Nicole LaBrosse | |||||||||||||||||
| Senior Vice President, Chief Financial Officer | |||||||||||||||||